Skip to main content
SpringerLink
Log in

Pharmacokinetic–Pharmacodynamic Modeling of the Antihypertensive Effect of Eprosartan in Black and White Hypertensive Patients

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Background and Objective

It is well recognized that many antihypertensive drugs exhibit large interindividual variability in effect and that this wide range of patient response to antihypertensive drugs is a major problem in achieving blood pressure (BP) control. Variability in both drug concentration and drug effect may cause the heterogeneity in antihypertensive drug response. However, for most antihypertensive drugs, no clear relationship between drug concentration and its effect on BP has been reported. This study aimed to describe the relationship between eprosartan exposure and its effect on the systolic blood pressure (SBP) using population pharmacokinetic–pharmacodynamic modeling. Interindividual variability in pharmacokinetics and pharmacodynamics was quantified and the influence of covariates on this relationship was evaluated.

Patients and Methods

Eprosartan plasma concentrations and SBP measurements were determined in 86 mildly hypertensive patients from the ROTATE study aged 48.1 ± 7.6 years with different ethnic backgrounds (33 White Dutch, 41 Creole Surinamese, 12 Hindustani Surinamese). In 12 of these patients, pharmacokinetics were densely sampled and 24-h ambulatory BP measurements were obtained. Data were analyzed using nonlinear mixed effects modeling.

Results

Eprosartan concentration–time profiles were adequately described with a two-compartment pharmacokinetic model with zero-order absorption. A log-linear relationship was used to describe the relationship between concentration and the decrease in SBP. A hypothetical effect compartment was used to describe hysteresis in the drug effect. Approximately 80 % of the maximum decrease in SBP was observed after 24 days. Interindividual variability in drug response was 65 % and decreased to 14 % when ethnicity was added as covariate. Creole Surinamese exhibited no drug response in contrast to White Dutch and Hindustani Surinamese [−2.6 mm Hg per (ng/ml)].

Conclusions

The developed pharmacokinetic–pharmacodynamic model allows the quantification and explanation of variability in SBP between individuals with ethnicity as a useful determinant of responsiveness to eprosartan.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Redon J, Brunner HR, Ferri C, et al. Practical solutions to the challenges of uncontrolled hypertension: a white paper. J Hypertens Suppl. 2008;26(4):S1–14.

    Article  PubMed  CAS  Google Scholar 

  2. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27(11):2121–58.

    Article  PubMed  CAS  Google Scholar 

  3. Gomez HJ, Cirillo VJ, Sromovsky JA, et al. Lisinopril dose–response relationship in essential hypertension. Br J Clin Pharmacol. 1989;28(4):415–20.

    Article  PubMed  CAS  Google Scholar 

  4. MacGregor GA, Banks RA, Markandu ND, et al. Lack of effect of beta-blocker on flat dose response to thiazide in hypertension: efficacy of low dose thiazide combined with beta-blocker. Br Med J (Clin Res Ed). 1983;286(6377):1535–8.

    Article  CAS  Google Scholar 

  5. Hansson L, Zweifler AJ, Julius S, et al. Propranolol therapy in essential hypertension. Observations on predictability of therapeutic response. Int J Clin Pharmacol. 1974;10(2):79–89.

    PubMed  CAS  Google Scholar 

  6. Meredith PA. Clinical relevance of optimal pharmacokinetics in the treatment of hypertension. J Hypertens Suppl. 1997;15(5):S27–31.

    Article  PubMed  CAS  Google Scholar 

  7. Donnelly R, Elliott HL, Meredith PA, et al. Concentration–effect relationships and individual responses to doxazosin in essential hypertension. Br J Clin Pharmacol. 1989;28(5):517–26.

    Article  PubMed  CAS  Google Scholar 

  8. Donnelly R, Elliott HL, Meredith PA, et al. Nifedipine: individual responses and concentration–effect relationships. Hypertension. 1988;12(4):443–9.

    Article  PubMed  CAS  Google Scholar 

  9. Donnelly R, Elliott HL, Meredith PA, et al. The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin. Eur J Clin Pharmacol. 1993;44(3):279–82.

    Article  PubMed  CAS  Google Scholar 

  10. Ackaert O, Van Rijn-Bikker PC, Snelder N, et al. Population modeling of blood pressure: assessing clinically important factors for cardiovasular disease. PAGE 20 (2011) Abstr 2025. www.page-meeting.org/?abstract=2025.

  11. van Rijn-Bikker PC, Mairuhu G, van Montfrans GA, et al. Genetic factors are relevant and independent determinants of antihypertensive drug effects in a multiracial population. Am J Hypertens. 2009;22(12):1295–302.

    Article  PubMed  Google Scholar 

  12. Li XN, Xu HR, Chen WL, et al. Determination of eprosartan in human plasma and urine by LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;853(1–2):47–53.

    PubMed  CAS  Google Scholar 

  13. Ferreiros N, Dresen S, Alonso RM, et al. Validated quantitation of angiotensin II receptor antagonists (ARA-II) in human plasma by liquid-chromatography-tandem mass spectrometry using minimum sample clean-up and investigation of ion suppression. Ther Drug Monit. 2007;29(6):824–34.

    Article  PubMed  CAS  Google Scholar 

  14. Tenero D, Martin D, Ilson B, et al. Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food. Biopharm Drug Dispos. 1998;19(6):351–6.

    Article  PubMed  CAS  Google Scholar 

  15. Williams B, Lindholm LH, Sever P. Systolic pressure is all that matters. Lancet. 2008;371(9631):2219–21.

    Article  PubMed  Google Scholar 

  16. Chapelsky MC, Martin DE, Tenero DM, et al. A dose proportionality study of eprosartan in healthy male volunteers. J Clin Pharmacol. 1998;38(1):34–9.

    Article  PubMed  CAS  Google Scholar 

  17. Tenero DM, Martin DE, Miller AK, et al. Effect of age and gender on the pharmacokinetics of eprosartan. Br J Clin Pharmacol. 1998;46(3):267–70.

    Article  PubMed  CAS  Google Scholar 

  18. Csajka C, Buclin T, Fattinger K, et al. Population pharmacokinetic–pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers. Clin Pharmacokinet. 2002;41(2):137–52.

    Article  PubMed  CAS  Google Scholar 

  19. Morsing P, Vauquelin G. How can the differences among AT1-receptor antagonists be explained? Cell Biochem Biophys. 2001;35(1):89–102.

    Article  PubMed  CAS  Google Scholar 

  20. Vauquelin G, Van Liefde I, Birzbier BB, et al. New insights in insurmountable antagonism. Fundam Clin Pharmacol. 2002;16(4):263–72.

    Article  PubMed  CAS  Google Scholar 

  21. Van Liefde I, Vauquelin G. Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol. 2009;302(2):237–43.

    Article  PubMed  Google Scholar 

  22. Chapman AB, Schwartz GL, Boerwinkle E, et al. Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int. 2002;61(3):1047–55.

    Article  PubMed  CAS  Google Scholar 

  23. Brewster LM, van Montfrans GA, Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med. 2004;141(8):614–27.

    Article  PubMed  Google Scholar 

  24. Flack JM, Sica DA, Bakris G, et al. Management of high blood pressure in blacks: an update of the International Society on Hypertension in blacks consensus statement. Hypertension. 2010;56(5):780–800.

    Article  PubMed  CAS  Google Scholar 

  25. Krause T, Lovibond K, Caulfield M, et al. Management of hypertension: summary of NICE guidance. BMJ. 2011;343:d4891.

    Article  PubMed  Google Scholar 

  26. Donnelly R, Elliott HL, Meredith PA. Antihypertensive drugs: individualized analysis and clinical relevance of kinetic–dynamic relationships. Pharmacol Ther. 1992;53(1):67–79.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Petra C. van Rijn-Bikker and Oliver Ackaert contributed equally to this work.

This work was financially supported in part by Solvay Pharmaceutical Weesp, the Netherlands. The sponsor had no role in the design and conduct of the study, collection, management, analysis and interpretation of the data, or manuscript preparation.

Petra C. van Rijn-Bikker, Oliver Ackaert, Nelleke Snelder, Reinier M. van Hest, Bart A. Ploeger, Richard P. Koopmans, and Ron A. A. Mathôt have no other conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy, Academic Medical Center, University of Amsterdam, Meibergdreef 9, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands

    Petra C. van Rijn-Bikker, Reinier M. van Hest & Ron A. A. Mathôt

  2. LAP&P consultants, Leiden, The Netherlands

    Oliver Ackaert & Nelleke Snelder

  3. Division of Pharmacology, Leiden/Amsterdam Center for Drug Research, Leiden University, Leiden, The Netherlands

    Bart A. Ploeger

  4. Department of Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands

    Richard P. Koopmans

Authors
  1. Petra C. van Rijn-Bikker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Oliver Ackaert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nelleke Snelder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Reinier M. van Hest
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bart A. Ploeger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Richard P. Koopmans
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ron A. A. Mathôt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Petra C. van Rijn-Bikker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Rijn-Bikker, P.C., Ackaert, O., Snelder, N. et al. Pharmacokinetic–Pharmacodynamic Modeling of the Antihypertensive Effect of Eprosartan in Black and White Hypertensive Patients. Clin Pharmacokinet 52, 793–803 (2013). https://doi.org/10.1007/s40262-013-0073-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-013-0073-6

Keywords

Search

Navigation